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CAPSULE SUMMARY 
• Previous studies reported conflicting results on possible associations between use of 
phosphodiesterase type 5 (PDE5) inhibitors and the risk of melanoma.  
• This meta-analysis of five observational studies suggested a slight but significant 
association between PDE5 inhibitors and both melanoma and basal cell carcinoma 
with some evidence of heterogeneity.  
• There were several limitations of this study, and future well-conducted prospective 
studies are warranted to assess this modest association. 
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ABSTRACT 
Background: The association between phosphodiesterase type 5 (PDE5) inhibitors and 
melanoma risk is controversial.  
Objective: We quantify the association between use of PDE5 inhibitors and melanoma. 
Methods: We systematically searched PubMed, Embase, CENTRAL, Web of Science, 
and ClinicalTrials.gov for studies up to July 13, 2016 evaluating the association between 
PDE5 inhibitors and skin cancer. Random effects meta-analyses were used to calculate 
the adjusted odds ratio (OR) with 95% confidence interval (CI). 
Results: Five observational studies were included. Compared with PDE5 inhibitor 
non-use, PDE5 inhibitor use was slightly but significantly associated with increased risk 
of melanoma (OR 1.12, 95% CI 1.03-1.21) and basal cell carcinoma (BCC) (OR 1.14, 
95% CI 1.09-1.19), but not squamous cell carcinoma (SCC). For melanoma risk, none of 
the pre-specified factors (dose of PDE5 inhibitors, study design, and study region) 
significantly affected the results (P>0.05). Our sensitivity analysis confirmed the stability 
of the results.  
Limitations: We included only observational studies, which had some heterogeneities 
and inconsistent controlling for potential confounders. 
Conclusions: Use of PDE5 inhibitors may be associated with a slightly increased risk of 
melanoma and BCC, but not SCC. However, further large well-conducted prospective 
studies with adequate adjustment for potential confounders are required for confirmation.  
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Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, tadalafil, and vardenafil 
inhibit cyclic guanosine-3’, 5’-monophosphate (cGMP)-degrading PDE5A in the vascular 
smooth muscle and are widely used treat erectile dysfunction1. Interestingly, activation of 
this cGMP pathway has been shown to promote melanoma cell growth and migration2, 3, 
and this link has recently been confirmed4. These laboratory observations have 
prompted several observational studies assessing the association between PDE5 
inhibitors and risk of melanoma 5-9.  
In 2014, the first cohort study on this subject (Li et al.) among a US-based cohort of male 
health professionals indicated that self-reported use of PDE5 inhibitors was significantly 
associated with higher risk of melanoma compared to non-use 5. However, their results 
were based on only 142 melanoma cases, of whom 14 used sildenafil. Since Li et al., 
four additional studies have been published. A nested case-control study (Loeb et al. 
2015) suggested a modest association between PDE5 inhibitors and risk of melanoma 
but did not meet several of Hill’s causality criteria 6. However, two epidemiological 
studies indicated no association 7, 9. Given these inconsistencies among individual 
studies, it is not possible to determine whether there is a link between PDE5 inhibitors 
and risk of melanoma.  
PDE5 inhibitors are an effective intervention and are recommended as first-line 
treatment for erectile dysfunction, which affects over 18 million men in the US, or up to 
20% of males aged 20 years or older10. With the expiration of the patents on sildenafil 
and other PDE5-inhibitor drugs, lower costs and more direct-to-consumer advertising will 
certainly increase the number of users. Understanding the possible connections 
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between PDE5 inhibitors and the incidence of melanoma is an important public health 
issue.  
We therefore conducted a study-level meta-analysis of available evidence from 
observational studies to quantify the possible association between use of PDE5 
inhibitors and risk of skin cancers. No randomized trials were available on this 
association. We also performed a cumulative meta-analysis and sensitivity analysis to 
assess the robustness of the results from available studies. 
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Methods 
Search strategy and study selection  
We searched PubMed, Embase, Cochrane Central Register of Controlled Trials 
(CENTRAL), Web of Science, and ClinicalTrials.gov to identify randomized trials or 
observational studies published up to July 13, 2016 that evaluated the association 
between exposure to PDE5 inhibitors and risk of skin cancer. We searched on combined 
terms-“(sildenafil or vardenadil or avanafil or tadalafil or phosphodiesterase type 5 or 
phosphodieterase-5 or PDE5) and (melanoma or basal cell carcinoma or squamous cell 
carcinoma or skin cancer)”- without any restriction. We selected the studies according to 
the following inclusion criteria: 1) randomized controlled trials, cohort studies, or 
case-control studies; 2) studies comparing PDE5 inhibitors with placebo or non-PDE5 
inhibitors; 3) follow-up for at least 52 weeks (not applicable to case-control studies), due 
to the fact that little information relevant to cancer incidence was reported in studies of 
shorter duration; 4) reporting the outcomes of skin cancer. The primary outcome of 
interest was risk of melanoma, and secondary outcomes included basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC). We excluded conference abstracts 
because they offer limited information with which to assess study quality, population, and 
outcomes. 
Data extraction and quality assessment  
We collected information on study design, drug use, study location, characteristics of 
participants, selection criteria, exposure definition, adjusted covariates, and outcomes of 
interest. Data on outcomes such as adjusted hazard ratio (HR), adjusted risk ratio (RR), 
and adjusted odds ratio (OR) were extracted if appropriate. The Cochrane risk of bias 
9  
tool for randomized trials 11 and the Newcastle-Ottawa quality-assessment scale (NOS) 
for observational studies12 were used to assess quality. For NOS criteria, a maximum of 
nine stars would be allocated to the following domains: selection, comparability, and 
outcome/exposure, with higher scores indicating better quality. Two reviewers (H.T. and 
W.W.) independently extracted the data and assessed the quality of each study. Any 
disagreements were resolved by consensus or referral to a third reviewer (J.H.).  
Statistical analysis  
Adjusted ORs with 95% confidence interval (CI) were used to pool the outcome data for 
PDE5 inhibitor users compared with non-users. Although the effect measures differed 
between cohort studies (HR) and case-control studies (OR), they are relative measures, 
and these two effect estimates are close when the event rate is low (<5%) 13, 14. A 
random-effect meta-analysis model was used because of potential heterogeneity across 
studies. Statistical heterogeneity was further quantified using the I² statistic, with I2 of 
<25%, ≥25% and <75%, and ≥75% indicating low, moderate, and high heterogeneity, 
respectively 15. Furthermore, meta-regression and subgroup analyses were performed to 
determine whether the pooled estimates were affected by total dose (low dose vs. 
medium dose vs. high dose), region of study (Europe vs. USA), type of design (cohort 
study vs. case-control study), and specific PDE5 inhibitors (sildenafil vs. vardenafil vs. 
tadalafil). The definitions of low dose, medium dose, and high dose in each study are 
presented in Supplemental Table 1. A sensitivity analysis omitting each study 
successively and a cumulative meta-analysis by order of publication year were carried 
out to assess the robustness of our findings. In addition, publication bias for risk of 
melanoma was assessed using Begg’s and Egger’s tests, as well as visual inspection of 
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the funnel plots. All statistical analyses were performed with STATA (Version 14; Stata 
Corp., College Station, TX). 
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RESULTS 
Study selection and study characteristics 
Of 294 citations retrieved from electronic databases, three cohort studies 5, 7, 8 and two 
case-control studies 6, 9 met the eligibility criteria and were included in our meta-analysis, 
involving a total of 998,456 participants (Fig 1). No randomized studies were identified. 
The characteristics of the included studies are presented in Table 1. In total, 15,916 
incident melanoma cases came from five studies, 46,785 incident BCC cases came from 
four studies, and 637 incident SCC cases came from two studies. However, two studies 
were performed using UK Clinical Practice Research Datalink (CPRD) 7, 8, which might 
have some overlapping patients. Both studies were included because they differed in 
study design and selection criteria. One study used the cohort study design including 
male patients newly diagnosed with erectile dysfunction aged ≥ 40 years from 1998 to 
2014 and those without any type of skin cancer diagnosis, who were never prescribed 
PDE 5 inhibitors before cohort entry 7. The other study used a matched cohort study 
design including male patients without any prior cancer diagnosis aged ≥ 18 years from 
1999 to 2014 and those who were prescribed a PDE5 inhibitor as the exposures, 
matched to four unexposed controls 8. The included studies were of adequate quality, 
with more than seven stars out of nine in the NOS quality assessment (Supplemental 
Table 2). 
Meta-analysis 
The meta-analysis demonstrated that PDE5 inhibitors increased the risk of melanoma 
(adjusted OR 1.12, 95% CI 1.03-1.21, I2 = 49.1%) and BCC (adjusted OR 1.14, 95% CI 
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1.09-1.19, I2 = 49.5%), with moderate heterogeneity. In contrast, there was no evidence 
of any increased risk of SCC among PDE5-inhibitor users (adjusted OR 1.04, 95% CI 
0.78-1.37, I2 = 16.9%) (Fig 2).  
Furthermore, meta-regression and subgroup analyses were performed to examine the 
source of heterogeneity (Table 2). The subgroup analysis by dose showed that the 
adjusted risk of melanoma was 1.06 (95% CI 0.95-1.19, I2 = 60.2%) for low-dose users, 
1.11 (95% CI 1.05-1.18, I2 = 0%) for medium-dose users, and 1.08 (95% CI 1.00-1.18, I2 
= 13.3%) for high-dose users (Supplemental Fig 1). Additionally, our meta-regression 
analysis indicated that the risk was not statistically different across the three dose 
subgroups (P for interaction = 0.62). Another subgroup analysis by region of study found 
a significantly increased risk of melanoma in the studies performed in Europe (adjusted 
OR 1.13, 95% CI 1.06-1.21, I2=0%), but not in the USA (adjusted OR 1.37, 95% CI 
0.64-2.93, I2=76.0%) (Supplemental Fig 2). Use of PDE5 inhibitors was significantly 
associated with increased risk of melanoma in cohort studies (adjusted OR 1.19, 95% CI 
1.01-1.40, I2=33.2%), but not in case-control studies (adjusted OR 1.09, 95% CI 
0.98-1.20, I2=63.3%) (Supplemental Fig 3). In addition, no individual PDE5 inhibitor 
was significantly associated with increased risk of melanoma (Supplemental Fig 4). 
There was no significant difference between these subgroups (P for interaction > 0.05).  
Sensitivity analysis and publication bias 
The significant association between PDE5 inhibitor use and increased risk of melanoma 
remained robust in the sensitivity analysis when each study was successively omitted 
(Supplemental Fig 5). When one of the studies based on the UK CPRD was excluded, 
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the result of excluding the study performed by either Lian Y et al. 7 (OR, 1.11; 95%CI, 
1.01 to 1.22) or Matthews A et al. 8 (OR, 1.11; 95%, 1.00 to 1.24) was similar to primary 
result. Our cumulative meta-analysis ordered by publication year indicated that PDE5 
inhibitor use was associated with a slight increase in risk of melanoma, and the point 
estimate gradually moved towards the null as the CI narrowed (Supplemental Fig 6). 
There was no evidence of substantial publication bias based on the Egger’s test (P = 
0.12), Begg’s test (P = 0.09) or visual inspection of the funnel plot (Supplemental Fig 7).  
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DISCUSSION 
Our meta-analysis of five observational studies involving a large number of total 
participants and incident cases of skin cancer provides evidence that PDE5 inhibitor use 
is slightly but significantly associated with increased risk of melanoma and BCC, but not 
SCC. For risk of melanoma, there was no evidence of dose-dependent association with 
PDE5 inhibitor use. Based on the results of a meta-regression, no other pre-specified 
factors (study design, study region, and type of PDE5 inhibitor) significantly affected the 
overall results. A significantly increased risk of melanoma was found in European 
populations, but not in US populations. Our cumulative meta-analysis indicated a weak 
association, and the point estimate gradually moved towards the null. Furthermore, the 
sensitivity analysis omitting each study successively confirmed the robustness of our 
results. However, our results should be interpreted with caution due to heterogeneity 
across studies.    
Several laboratory studies have reported that PDE5 inhibitors might promote melanoma 
cell growth and migration through activation of the cGMP pathway 2-4. Recently, a 
cGMP-dependent mitogen-activated protein kinase (MAPK) pathway was identified in 
melanoma cells as the link between sildenafil use and increased melanoma risk 4. 
Nevertheless, laboratory studies are warranted to examine the effect of the intermittent 
use of PDE5 inhibitors on inducing irreversible changes in gene expression and 
promoting melanoma development 5. However, evidence of an epidemiological 
association between the use of PDE5 inhibitors and risk of melanoma remains 
inconsistent. One study showed that PDE5 inhibitor use was not associated with overall 
elevated risk of melanoma, though the risk was significantly higher among those who 
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had received seven or more prescriptions or ≥25 pills 7. Our findings did not indicate a 
strong dose-response relationship between the use of PDE5 inhibitors and risk of 
melanoma. Therefore, we must interpret this association with caution.  
We found a significantly increased risk of melanoma associated with PDE5 inhibitors 
only in European populations, but not in U.S. populations. It should be noted that an 
increased risk of melanoma was observed in U.S. populations, but it did not reach 
statistical significance. Factors that might explain the differences in risk of melanoma 
associated with PDE5 inhibitor use among these populations include socioeconomic and 
cultural differences.  
Furthermore, the association between PDE5 inhibitor use and risk of melanoma might be 
influenced by potential confounders. Matthews A et al. showed that this significant 
association might be confounded by greater sun exposure among users of PDE5 
inhibitors8. Their post hoc analysis showed that solar keratosis was significantly 
associated with PDE5 inhibitor use, which indicated that men with higher sun exposure 
were more likely to take PDE5 inhibitors8. However, further meta-analysis was limited by 
lack of data on sun exposure in individual studies. Additionally, our meta-analysis found 
a similar increase in risk of BCC, but there was no increase in the risk of SCC. Melanoma 
is more closely related to intermittent sun exposure, whereas non-melanoma skin cancer 
is more related to chronic sun exposure. Further studies are necessary to clarify the 
potential effect modification and confounding by sun exposure. In addition, a study by 
Loeb et al. indicated that PDE5 inhibitor users had higher educational levels and annual 
income, which were also significantly associated with melanoma risk. Finally, the study 
by Pottegård A et al. found an increased incidence of lower stage/grade of melanoma 
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among PDE5 inhibitor users than non-users, which suggested that the slightly elevated 
risk of melanoma might be attributable to more health-seeking behaviors, resulting in 
earlier detection9. The causality remains elusive, and further well-conducted large-scale 
prospective studies or randomized trials are still needed to confirm our findings.  
Our study has several strengths. First, this is the first meta-analysis to address 
the association between PDE5 inhibitors and risk of melanoma by including all 
relevant literature to date. Second, we performed subgroup analysis, sensitivity 
analysis, and cumulative meta-analysis to confirm the robustness of our 
findings. We also acknowledge that our meta-analysis has several limitations. 
First, no randomized controlled trials were identified, despite a systematic 
search of electronic databases. Second, doses were stratified differently across 
studies; this might contribute to the observed heterogeneity, which might also 
have affected the results of our subgroup analysis by dose. Third, two studies 
were performed in the same database over the same time period, which might 
result in some overlapping patients7, 8. Both studies were included due to the 
fact that they differed in study design and patient selection. Furthermore, 
excluding each study produced results similar to the primary results. Fourth, we 
were unable to determine the potential confounding effect of ultraviolet radiation 
exposure, skin type, or family history of melanoma. In addition, adjustment 
among studies for other confounders (e.g., age, immunosuppression, social 
economic status, and marital status) was inconsistent. Finally, our 
meta-analysis detected statistical heterogeneity, which might be due (at least in 
part) to the study of different geographic regions.    
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In conclusion, some evidence suggests that use of PDE5 inhibitors may be 
slightly associated with increased risk of melanoma and BCC, but not SCC. 
Further large, well-conducted prospective studies with clear definitions of dose 
and duration of PDE5 inhibitors and adequate adjustment for potential 
confounders (e.g., ultraviolet exposure) are required for confirmation.
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Abbreviations used:  
PDE5: phosphodiesterase type 5 
cGMP: cyclic guanosine-3’, 5’-monophosphate 
MAPK: mitogen-activated protein kinase 
OR: odds ratio  
HR: hazard ratio. 
CI: confidence interval 
BCC, basal cell carcinoma 
SCC, squamous cell carcinoma 
NOS, Newcastle-Ottawa quality-assessment scale 
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Figure legends:   
Fig 1. Flow chart of the identification of eligible studies  
Fig 2. Meta-analysis of the association between phosphodiesterase type 5 inhibitor use 
and risk of skin cancer 
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Table 1. Characteristics of included studies 1 
Study Study design and data 
source 
No. of 
participan
ts  
Age 
(years) 
Selection criteria Exposure 
definition 
Non- 
exposure 
definition 
 
Adjusted covariate  
Li WQ et al. 
(2014) [5]  
Prospective cohort study; 
Health Professionals 
Follow-up Study (HPFS); 
USA, 1986-2000 
Sildenafil: 
727; 
Non-silde
nafil: 
14,185 
Mean: 
64 
Men aged 40-75 
years, who 
completed a 
baseline 
questionnaire on 
medical history and 
lifestyle practices 
Sildenafil Unexposed 
to sildenafil 
Age, body mass index, 
smoking, physical activity, 
childhood reaction to sun, 
times of sunburns, mole 
count, hair color, family 
history of melanoma, sun 
exposure, UV index, as well 
as other treatment for 
erectile function problems. 
Loeb S et 
al. (2015) 
[6]  
Nested case-control study; 
Swedish Prescribed Drug 
Register, Swedish 
Melanoma Register, and 
other health care registers 
and demographic 
databases; Sweden, 
2006-2012 
PDE5 
inhibitors: 
2,148; 
Non- 
PDE5 
inhibitors: 
22,242 
Median:
73 
Incident melanoma 
cases without other 
cancers were 
randomly matched 
to 5 cancer-free 
controls 
Prescribed 
PDE5 
inhibitors 
since 2006 
Not-prescri
bed PDE5 
inhibitors 
CCI, marital status, 
educational level and 
disposable income 
Lian Y et al. 
(2016) [7]  
Prospective cohort study; 
UK Clinical Practice 
Research Datalink 
(CPRD); UK, 1998 - 2014 
PDE5 
inhibitors: 
58,732; 
Non-PDE
5 
inhibitors: 
84,611 
Mean:5
9 
Erectile dysfunction 
patients aged ≥40 
years, have at least 
1 year of baseline 
medical history, and 
have never been 
prescribed PDE5 
inhibitors at any 
time before cohort 
entry; excluded 
patients diagnosed 
with any type of 
skin cancer before 
cohort entry 
PDE5 
inhibitors; at 
least 1 year 
of follow-up 
after cohort 
entry 
Unexposed 
until the 
year after 
the first 
PDE5 
inhibitor 
prescription  
 
Age, year of cohort entry, 
alcohol-related disorders, 
smoking status, BMI, 
precancerous skin lesions, 
presence of naevi, 
immunosuppression, use of 
antiparkinsonian drugs, CCI, 
number of different drug 
classes used, and number of 
physician visits in the year 
before cohort entry, and 
health-seeking– related 
variables 
Matthews A 
et al. (2016) 
[8]  
Prospective matched 
cohort study; 
UK Clinical Practice 
Research Datalink 
PDE5 
inhibitors: 
145,104; 
Non- 
Median:
57 
All adult men 
initiating a PDE5 
inhibitor and with no 
prior cancer 
PDE5 
inhibitors; at 
least 1 year 
of follow-up 
Unexposed  
to PDE5 
inhibitors at 
least 1 year 
Age, alcohol use, number of 
consultations in year before 
index date, BMI category, 
alcohol use, smoking status  
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(CPRD);UK,1999-2014 PDE5 
inhibitors: 
560,933 
diagnosis were 
identified 
and matched on 
age, diabetes 
status, and 
general practice to 
up to four 
unexposed controls  
prior to the 
first 
prescription 
record 
of follow-up 
prior to the 
index date 
of the 
exposed 
patient 
Pottegård 
A et al. 
(2016) [9]  
Case–control study; 
Danish Nationwide Health 
Registries (DNHR);  
Denmark, 2000-2012 
Kaiser Permanente 
Northern California 
(KPNC) electronic health 
records; USA, 2000-2014 
DNHR: 
PDE5 
inhibitors：
4,603; 
Non-PDE
5 
inhibitors: 
72,892  
KPNC: 
PDE5 
inhibitors：
6033; 
Non-PDE
5 
inhibitors: 
26,246 
 
NR Men with 
histologically 
verified melanoma 
(cases) 
matched on birth 
year to 10 
cancer-free controls 
Two or more 
filled 
prescriptions 
for any 
PDE5 
inhibitors 
prior to the 
index date 
None or one 
filled 
prescription 
of any 
PDE5 
inhibitors 
Age and calendar time, use 
of oral steroids, 
weak/moderate topical 
steroids, strong/very strong 
topical steroids, thiazides, 
beta-blockers, angiotensin-II 
receptor blockers, low-dose 
aspirin (only in the DNHR), 
non-aspirin non-steroidal 
anti-inflammatory drugs, 
antidepressants, and statins; 
(b) diagnoses of 
non-melanoma skin cancer, 
type 1 or type 2 diabetes, 
chronic obstructive 
pulmonary disease, 
alcohol-related disease, and 
moderate to severe renal 
disease; and (c) highest 
education achieved (in the 
DNHR) and socioeconomic 
level based on the US 
Census block of residence 
(in the KPNC database). 
 PDE5, phosphodiesterase type 5; NR, not reported. UV, ultraviolet; BMI, body mass index; CCI, Charlson comorbidity index 2 
 3 
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Table 2. Subgroup analysis of association between PDE5 inhibitors and risk of 5 
melanoma 6 
 7 
  Number of 
studies 
Adjusted odds ratio 
(95%CI) 
I2 (%) P for 
interaction 
Overall  5 1.12 (1.03,1.21) 49.1 - 
Total dose 
 Low dose 4 1.06 (0.95, 1.19) 60.2 0.62 
 Medium dose 4 1.11 (1.05, 1.18) 0 
 High dose 4 1.08 (1.00, 1.18)  13.3  
Region of study 
 Europe 4 1.13 (1.06, 1.21) 0 0.35 
 USA 2 1.37 (0.64, 2.93) 76 
Design of study 
 Cohort study 3 1.19 (1.01, 1.40) 33.2 0.46 
 Case-control study 2 1.09 (0.98, 1.20) 49.1 
Type of PDE5 inhibitor 
 Sildenafil 3 1.08 (0.97, 1.21) 49.4 0.30 
 Vardenafil 1 1.03 (0.91, 1.17) - 
 Tadalafil 1 1.06 (0.88, 1.28) - 
 Vardenafil or tadalafil 1 1.16 (0.99, 1.36) - 
 8 9 
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